Questions and answers

Numerous studies have demonstrated that chemically modifying the natural gelatin in proteins can extend their half-life; this has led to the development of the GLK protein-based half-life extension. Recently, the genetic fusing of a glycoprotein to an artificial GLK polypeptide with the goal of combating leukemia has produced a half-life prolonging effect. According to the study, the GLK-modified glycoprotein had a terminal plasma half-life that was 5.7 times longer and had comparable in vivo bioactivity. Interestingly, an antibody response was only found against the heterologous domain following mouse immunization—not against the GLK portion. GLK modification has a high scientific and practical importance since it is both efficacious and low immunogenicity, and it can prolong the half-life of target medications while lowering adverse effects.